Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus docetaxel versus docetaxel as second-line treatment for advanced esophageal squamous cell carcinoma
ChiCTR1800020008Phase 4Not yet recruiting
- Sponsor
- Nanyang Central Hospital
- Start
- Mar 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anlotinib and docetaxel in Esophageal Squamous Cell Carcinoma (ESCC) and esophageal cancer, sponsored by Nanyang Central Hospital. Primary endpoint: progression-free survival. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
anlotinibdocetaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal cancer
Beyond the preview
Go deeper on ChiCTR1800020008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020008.